FDA Expands Indications for Lutetium Lu 177 Vipivotide Tetraxetan to Include Patients with PSMA Positive mCRPC By Ogkologos - April 25, 2025 633 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the PSMAfore study Source RELATED ARTICLESMORE FROM AUTHOR Mortality Trends for Most Cancers Remain Favourable In the EU, Although the Absolute Number of Cancer Deaths Is Not Declining Due To Population Ageing Abemaciclib Improves PFS at Six Months Among Patients with High-Grade Meningiomas Harbouring NF2 or CDK Pathway Alterations N-of-1 Tailored Combination Therapy Matched to the Molecular Alterations, Facilitated by Personalised Dosing, Is Associated with Safety and Activity MOST POPULAR How Anxiety Impacts People With Cancer and How to Cope February 10, 2022 Want to learn more about Sulforaphanes? December 4, 2020 Intracranial Efficacy of Pembrolizumab in Patients with Brain Metastases June 20, 2023 Subcutaneous Daratumumab Monotherapy for Patients with High-Risk Smoldering Multiple Myeloma December 18, 2024 Load more HOT NEWS Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate... Similar Disease-Free Survival with Extended Intermittent or Continuous Treatment with Letrozole... Por qué la Reunión Anual de la American Society of Clinical... Significant Intracranial Efficacy and Survival Benefits of Osimertinib in Patients with...
